Sunday, November 8, 2026

USD/EUR Rises By 2% In The Last 21 Sessions

USD/EUR Rises By 2% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.92% for the last 21 sessions. At 15:10 EST on Sunday, 4 June, USD/EUR (USDEUR) is $0.93.

USD/EUR's yearly highs and lows, it's 3.572% up from its 52-week low and 10.933% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.09%, a positive 0.08%, and a positive 0.40%, respectively.

USD/EUR's highest amplitude of average volatility was 0.27% (last week), 0.26% (last month), and 0.40% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Speculator investors set to re-position short usd/jpy above 140 – ING. According to FXStreet on Friday, 2 June, "However, USD/JPY looks overvalued relative to the terms of trade story - which is much better for the Yen than a year ago.", "And thus it would not be a surprise to see speculator investors trying to re-position short USD/JPY above 140 - even if such a strategy has already proved painful this year."
  • Usd/jpy price analysis: bears occupy driver’s seat despite snapping four-day downtrend near 139.00. According to FXStreet on Friday, 2 June, "However, a one-week-old previous support line, close to 139.15 at the latest, restricts the USD/JPY pair's immediate upside within a short-term bearish channel, currently between 138.35 and 139.50.", "On the flip side, a clear break of 138.35 will also reject the previously stated bearish channel but in favor of the USD/JPY sellers. "
  • Usd/jpy surges above 139.50 following US NFP figures. According to FXStreet on Friday, 2 June, "On the other hand, immediate support for USD/JPY is seen at the 138.90 zone level, followed by the 138.50 level and the psychological mark at 138.00.", "The USD/JPY gained more than 60 pips on Friday, spiking to the 139.70 zone following the labor market data from the US which suggested that the Federal Reserve (Fed) may reconsider a further hike. "
  • Speculator investors set to re-position short usd/jpy above 140 – ING. According to FXStreet on Friday, 2 June, "However, USD/JPY looks overvalued relative to the terms of trade story - which is much better for the Yen than a year ago.", "And thus it would not be a surprise to see speculator investors trying to re-position short USD/JPY above 140 - even if such a strategy has already proved painful this year."
  • Usd/jpy spikes and retreats on mixed US NFP report, up a little above 139.00 mark. According to FXStreet on Friday, 2 June, "This, along with the risk-on impulse, as depicted by a generally positive tone around the equity markets, undermines the safe-haven Japanese Yen (JPY) and acts as a tailwind for the USD/JPY pair, warranting some caution for bearish traders.", "The reading consensus estimates pointing to an addition of 190K jobs and well above the previous month's upwardly 294K, which, in turn, benefits the Greenback and provides a modest lift to the USD/JPY pair."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com